Hecht Beth — SEC insider filings
SEC reporting owner CIK 1652410. 32 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-08-17 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 14 filings — 265,000 shares, $1,935,442 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: sale of 25,000 shares @ $10.23 ($255,828) in Xeris Biopharma Holdings, Inc., filed 2026-11-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | See Remarks | 21 | — | 15 legs · 265,000 sh · $1,935,442 | 28 |
| Iterum Therapeutics plc (ITRM) | Director | 6 | — | — | 9 |
| XERIS PHARMACEUTICALS INC (XERS) | See Remarks | 3 | — | — | 9 |
| Neos Therapeutics, Inc. (NEOS) | Director | 1 | — | — | 6 |
| AYTU BIOPHARMA, INC (AYTU) | Director | 1 | — | — | 1 |
Insider filings — Hecht Beth
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 25,000 @ $10.23 | EDGAR |
| 2026-10-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,666 @ $9.41 | EDGAR |
| 2026-09-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,666 @ $8.49 | EDGAR |
| 2026-08-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,666 @ $8.01 | EDGAR |
| 2026-07-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,666 @ $8.03 | EDGAR |
| 2026-06-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $6.06 | EDGAR |
| 2026-05-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $6.23 | EDGAR |
| 2026-04-03 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $5.99 | EDGAR |
| 2026-03-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,567 @ $6.24 · Sale (S): 100 @ $7.06 | EDGAR |
| 2026-02-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 121,293 @ $0 · Tax withholding (F): 98,375 @ $7.36 · Tax withholding (F): 46,914 @ $7.36 · Tax withholding (F): 24,266 @ $7.36 · Sale (S): 16,667 @ $7.45 · Grant/award (A): 162,162 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $7.43 | EDGAR |
| 2025-12-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $7.01 | EDGAR |
| 2025-11-13 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 16,667 @ $7.40 | EDGAR |
| 2025-03-21 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 40,000 @ $5.43 | EDGAR |
| 2025-02-03 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 45,909 @ $3.56 · Tax withholding (F): 98,375 @ $3.56 · Grant/award (A): 185,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 32,039 @ $3.61 | EDGAR |
| 2024-08-09 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 14,037 @ $2.11 · Tax withholding (F): 4,448 @ $2.11 · Tax withholding (F): 33,488 @ $1.12 · Tax withholding (F): 21,177 @ $1.26 · Tax withholding (F): 5,784 @ $1.24 · Tax withholding (F): 33,488 @ $2.24 · +2 more | EDGAR |
| 2024-01-31 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 750,000 @ $0 | EDGAR |
| 2023-06-15 | 4 | Iterum Therapeutics plc (ITRM) | Option exercise (M): 15,853 @ $0 · Option exercise (M): 15,853 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 350,000 @ $0 | EDGAR |
| 2022-06-24 | 4 | Iterum Therapeutics plc (ITRM) | Option exercise (M): 36,798 @ $0 · Option exercise (M): 36,798 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Iterum Therapeutics plc (ITRM) | Grant/award (A): 237,795 (derivative) @ $0.01 | EDGAR |
| 2022-03-22 | 4 | Iterum Therapeutics plc (ITRM) | Option exercise (M): 7,642 @ $0 · Option exercise (M): 7,642 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 225,000 @ $0 | EDGAR |
| 2021-10-05 | 4 | XERIS PHARMACEUTICALS INC (XERS) | Disposition to issuer (D): 26,366 · Disposition to issuer (D): 180,000 · Disposition to issuer (D): 30,879 (derivative) · Disposition to issuer (D): 65,295 (derivative) · Disposition to issuer (D): 3,826 (derivative) · Disposition to issuer (D): 32,500 (derivative) · +1 more | EDGAR |
| 2021-10-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 26,366 · Grant/award (A): 180,000 · Grant/award (A): 30,879 (derivative) · Grant/award (A): 65,295 (derivative) · Grant/award (A): 3,826 (derivative) · Grant/award (A): 32,500 (derivative) · +1 more | EDGAR |
| 2021-06-25 | 4 | Iterum Therapeutics plc (ITRM) | Grant/award (A): 36,798 (derivative) @ $0 | EDGAR |
| 2021-04-12 | 4 | AYTU BIOPHARMA, INC (AYTU) | Grant/award (A): 6,500 @ $0 | EDGAR |
| 2021-03-19 | 4 | Neos Therapeutics, Inc. (NEOS) | Disposition to issuer (D): 23,453 · Disposition to issuer (D): 12,500 (derivative) @ $0 · Disposition to issuer (D): 14,777 (derivative) @ $0 · Disposition to issuer (D): 18,322 (derivative) @ $0 · Disposition to issuer (D): 22,756 (derivative) @ $0 · Disposition to issuer (D): 46,907 (derivative) @ $0 | EDGAR |
| 2021-03-19 | 4 | Iterum Therapeutics plc (ITRM) | Grant/award (A): 7,642 (derivative) @ $0 | EDGAR |
| 2021-02-01 | 4 | XERIS PHARMACEUTICALS INC (XERS) | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2020-08-17 | 4 | XERIS PHARMACEUTICALS INC (XERS) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1652410 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs